Table 7.
Odds ratio (OR) and 95% confidence interval (CI) of the clinicopathological characteristics and MMP-11 rs28382575 genotypic frequencies in 578 patients with prostate cancer.
| Variable | Genotypic Frequencies | |||
|---|---|---|---|---|
| rs28382575 | TT (n = 541) | TC + CC (n = 37) | OR (95% CI) | p-Value |
| Pathologic Gleason grade group | ||||
| 1 + 2 + 3 | 453 (83.7%) | 30 (81.1%) | 1.00 | p = 0.674 |
| 4 + 5 | 88 (16.3%) | 7 (18.9%) | 1.201 (0.511–2.821) | |
| Clinical T stage | ||||
| 1 + 2 | 468 (86.5%) | 32 (86.5%) | 1.00 | p = 0.997 |
| 3 + 4 | 73 (13.5%) | 5 (13.5%) | 1.002 (0.378–2.654) | |
| Pathologic T stage | ||||
| 2 | 281 (51.9%) | 25 (67.6%) | 1.00 | p = 0.065 |
| 3 + 4 | 260 (48.1%) | 12 (32.4%) | 0.519 (0.255–1.054) | |
| Pathologic N stage | ||||
| N0 | 495 (91.5%) | 34 (91.9%) | 1.00 | p = 0.934 |
| N1 | 46 (8.5%) | 3 (8.1%) | 0.949 (0.281–3.211) | |
| Seminal vesicle invasion | ||||
| No | 419 (77.4%) | 32 (86.5%) | 1.00 | p = 0.199 |
| Yes | 122 (22.6%) | 5 (13.5%) | 0.537 (0.205–1.407) | |
| Perineural invasion | ||||
| No | 143 (26.4%) | 12 (32.4%) | 1.00 | p = 0.425 |
| Yes | 398 (73.6%) | 25 (67.6%) | 0.749 (0.366–1.529) | |
| Lymphovascular invasion | ||||
| No | 450 (83.2%) | 31 (83.8%) | 1.00 | p = 0.924 |
| Yes | 91 (16.8%) | 6 (16.2%) | 0.957 (0.388–2.361) | |
| D’Amico classification | ||||
| Low/Intermediate risk | 262 (48.4%) | 17 (45.9%) | 1.00 | p = 0.770 |
| High risk | 279 (51.6%) | 20 (54.1%) | 1.105 (0.566–2.155) | |
The ORs analyzed by their 95% CIs were estimated by logistic regression models.